Neuronetics, Inc. (STIM) earnings
STIM earnings moved a median of +3.03% by the close. Quarterly and annual STIM reports and results, each read against the price at its own news timestamp. Back to the STIM overview →
34 measured STIM earnings events.
Where these STIM earnings landedvs 34 measured STIM earnings reactions
| Middle 50% of STIM earnings reactions | -4.98% to +6.83% |
|---|---|
| Median reaction (to close) | +3.03% |
| Measured reactions | 34 |
Point-in-time · zero look-ahead
Half of the 34 STIM earnings events with a measured close landed between -4.98% and +6.83%; 62% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Neuronetics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +2.83% | +0.94% | |
| Neuronetics Reports Second Quarter 2026 Financial and Operating Results | Press release | +11.90% | +16.85% | |
| Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call | Press release | -0.97% | +3.31% | |
| Form 10-Q Neuronetics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +4.85% | +5.34% | |
| Neuronetics Reports First Quarter 2026 Financial and Operating Results | Press release | +4.85% | +5.34% | |
| Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call | Press release | +1.23% | -7.97% | |
| Form 10-K Neuronetics, Inc. For: Dec 31 | SEC filing · Form 10-K | -17.07% | -0.41% | |
| Neuronetics to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call | Press release | +5.04% | +6.72% | |
| Form 10-Q Neuronetics, Inc. For: Sep 30 | SEC filing · Form 10-Q | +13.65% | +20.59% | |
| Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan | Press release | +13.65% | +20.59% | |
| Neuronetics to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call | Press release | +0.15% | +5.88% | |
| Form 10-Q Neuronetics, Inc. For: Jun 30 | SEC filing · Form 10-Q | -1.74% | +10.58% | |
| Neuronetics Reports Second Quarter 2025 Financial and Operating Results | Press release | -1.74% | +10.58% | |
| Neuronetics to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call | Press release | +0.26% | +7.93% | |
| Form 10-Q Neuronetics, Inc. For: Mar 31 | SEC filing · Form 10-Q | -6.00% | +22.62% | |
| Neuronetics Reports First Quarter 2025 Financial and Operating Results | Press release | -6.00% | +22.62% | |
| Neuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call | Press release | +1.16% | +4.63% | |
| Form 10-K Neuronetics, Inc. For: Dec 31 | SEC filing · Form 10-K | -3.25% | -5.75% | |
| Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call | Press release | -2.95% | -13.05% | |
| CORRECTION—Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results | Press release | -8.70% | -11.65% | |
| Form 10-Q Neuronetics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -28.57% | -10.39% | |
| Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results | Press release | -28.57% | -10.39% | |
| Neuronetics to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call | Press release | +0.00% | +5.94% | |
| Form 10-Q Neuronetics, Inc. For: Jun 30 | SEC filing · Form 10-Q | -20.24% | -40.40% | |
| Neuronetics Reports Record Second Quarter 2024 Financial and Operating Results | Press release | -20.24% | -40.40% | |
| Neuronetics to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call | Press release | +0.00% | +0.53% | |
| Form 10-Q Neuronetics, Inc. For: Mar 31 | SEC filing · Form 10-Q | -0.76% | -2.67% | |
| Neuronetics Reports Record First Quarter 2024 Financial and Operating Results | Press release | -6.27% | -27.58% | |
| Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call | Press release | -1.57% | -1.83% | |
| Form 10-K Neuronetics, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.25% | +2.74% | |
| Neuronetics to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call | Press release | -1.32% | +0.00% | |
| Form 10-Q Neuronetics, Inc. For: Sep 30 | SEC filing · Form 10-Q | +3.55% | +3.55% | |
| Neuronetics Reports Third Quarter 2023 Financial and Operating Results | Press release | — | +6.87% | |
| Neuronetics to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call | Press release | +0.00% | +1.89% |
Keep exploring
More STIM: analyst actions → · SEC filings → · STIM overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| UROVANT SCIENCES LTD COMMON (UROV) | 397 | 0.00% | 49% |
| Bruker Corporation (BRKR) | 395 | -0.10% | 46% |
| Axogen, Inc. (AXGN) | 393 | -0.12% | 48% |
| Fulgent Genetics, Inc. (FLGT) | 393 | +0.04% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.